Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master Protocol Trial of Tirzepatide and Retatrutide in Adults With MASLD at High Risk for Major Adverse Liver Outcomes
jRCT2021250031Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised trial of tirzepatide and retatrutide in metabolic dysfunction-associated steatotic liver disease (MASLD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO). Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCT2021250031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250031.